Clinical Effect of Fangfeng Tongshengsan on Post-chemoembolization Syndrome with Primary Liver Cancer or Postoperative Liver Metastases of Colorectal Cancer

YANG Lin; LIU Fangling; WU Yan; YANG Guowang; FU Qi; FAN Qingsheng; ZHANG Qing; WANG Xiaomin

doi:10.13422/j.cnki.syfjx.202202021

您当前的位置：

首页 >

文章列表页 >

Clinical Effect of Fangfeng Tongshengsan on Post-chemoembolization Syndrome with Primary Liver Cancer or Postoperative Liver Metastases of Colorectal Cancer

更新时间：2023-06-30

- Clinical Effect of Fangfeng Tongshengsan on Post-chemoembolization Syndrome with Primary Liver Cancer or Postoperative Liver Metastases of Colorectal Cancer
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 29, Issue 15, Pages: 103-109(2023)
- 作者机构：
  
  1.首都医科大学附属北京中医医院，北京 100010
  2.滦平县中医院，河北承德 068250
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.202202021
  CLC： R22;R242;R2-031;R287
- Received：14 July 2022，
  
  Published Online：17 August 2022，
  
  Published：05 August 2023
- 稿件说明：
移动端阅览
杨霖,刘方伶,吴岩等.防风通圣散治疗原发性肝癌和结直肠癌术后肝转移介入栓塞后综合征的临床疗效观察[J].中国实验方剂学杂志,2023,29(15):103-109.

YANG Lin,LIU Fangling,WU Yan,et al.Clinical Effect of Fangfeng Tongshengsan on Post-chemoembolization Syndrome with Primary Liver Cancer or Postoperative Liver Metastases of Colorectal Cancer[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(15):103-109.
杨霖,刘方伶,吴岩等.防风通圣散治疗原发性肝癌和结直肠癌术后肝转移介入栓塞后综合征的临床疗效观察[J].中国实验方剂学杂志,2023,29(15):103-109. DOI： 10.13422/j.cnki.syfjx.202202021.

YANG Lin,LIU Fangling,WU Yan,et al.Clinical Effect of Fangfeng Tongshengsan on Post-chemoembolization Syndrome with Primary Liver Cancer or Postoperative Liver Metastases of Colorectal Cancer[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(15):103-109. DOI： 10.13422/j.cnki.syfjx.202202021.

摘要

目的

观察防风通圣散对原发性肝癌和结直肠癌术后肝转移介入化疗栓塞后综合征的疗效。

方法

将原发性肝癌和结直肠癌术后肝转移患者接受经导管肝动脉化疗栓塞术并发生栓塞后综合征的患者72例随机分为治疗组（防风通圣散）和对照组（酒精擦浴+冰袋物理降温），每组36例；治疗组服用防风通圣散汤剂，对照组予以酒精擦浴联合冰袋物理降温，2组疗程均7 d。期间，观察2组患者发热、卡式评分、肝区疼痛、恶心、呕吐、便秘和肝功能情况。

结果

与对照组比较，治疗组治疗后患者发热情况明显改善，体温明显降低（

0.05），发热持续时间明显缩短（

0.05），提示防风通圣散能明显改善介入化疗栓塞后综合征患者体温情况；与对照组比较，治疗组患者卡氏评分明显升高（

0.05）；与对照组比较，治疗组患者疼痛情况明显缓解，疼痛时间明显缩短（

0.05）；此外，防风通圣散治疗后患者恶心、呕吐、便秘程度明显减轻（

0.05），恶心、呕吐、便秘持续时间明显缩短（

0.05）；同时，治疗组患者肝功能相关指标血清丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、

-谷氨酰转肽酶（GGT）、总胆红素（TBIL）水平均明显降低（

0.05），提示防风通圣散能明显改善介入化疗栓塞后综合征患者肝功能损伤情况。

结论

防风通圣散对原发性肝癌和结直肠癌术后肝转移介入化疗栓塞后综合征有较好的疗效。

Abstract

Objective

To observe the effect of the Fangfeng Tongshengsan on post-chemoembolization syndrome with primary liver cancer or postoperative liver metastases of colorectal cancer.

Method

Seventy-two patients suffered from post-chemoembolization syndrome after transcatheter hepatic arterial chemoembolization were randomly divided into 2 groups， including a Fangfeng Tongshengsan group and a control group， with 36 patients in each group. The patients in Fangfeng Tongshengsan group orally took the decoction for consecutive 7 d. The patients in the control group were physically cooled down with alcohol rub bath and ice pack for consecutive 7 d. Furthermore， the difference of fever， Karnofsky performance status （KPS）， pain in the liver region， nausea vomiting， constipation， and liver function between these two groups were observed.

Result

Compared with the control group， Fangfeng Tongshengsan significantly relieved fever， reduced the body temperature （

0.05）， and shortened the duration of fever （

0.05）， indicating that Fangfeng Tongshengsan remarkably improved the KPS （

0.05）. Meanwhile， Fangfeng Tongshengsan obviously alleviated nausea， vomiting， and constipation status and shortened the duration time compared with the control group （

0.05）. In addition， the parameters of liver function including alanine aminotransferase （ALT）， aspartate aminotransferase （AST），

-glutamyl transpeptidase （GGT）， and total bilirubin （TBIL） were significantly decreased in the Fangfeng Tongshengsan group （

0.05）， which indicated that Fangfeng Tongshengsan alleviated liver dysfunction of patients with post-chemoembolization syndrome.

Conclusion

Fangfeng Tongshengsan can be used to treat post-chemoembolization syndrome with primary liver cancer and postoperative liver metastases of colorectal cancer.

关键词

Keywords

references

陈万青，李贺，孙可欣，等 . 2014年中国恶性肿瘤发病和死亡分析［J］. 中华肿瘤杂志， 2018 ， 40 （ 1 ）： 5 - 13 .

ADAM R ， VINET E . Regional treatment of metastasis： Surgery of colorectal liver metastases ［J］. Ann Oncol ， 2004 ， 15 （ Suppl 4 ）： 103 - 106 .

SIEGEL R L ， Miller K D ， SAUER A G ， et al . Colorectal cancer statistics， 2020 ［J］. CA Cancer J Clin ， 2020 ， 70 （ 3 ）： 145 - 164 .

GIANNIS D ， SIDERIS G ， KAKOS C D ， et al . The role of liver transplantation for colorectal liver metastases： A systematic review and pooled analysis ［J］. Transplant Rev （Orlando）， 2020 ， 34 （ 4 ）： 100570 .

TANIAI N ， AKIMARU K ， YOSHIDA H ， et al . Surgical treatment for better prognosis of patients with liver metastases from colorectal cancer ［J］. Hepatogastroenterology ， 2007 ， 54 （ 78 ）： 1805 - 1809 .

QIN S ， LIU G J ， HUANG M ， et al . The local efficacy and influencing factors of ultrasound-guided percutaneous microwave ablation in colorectal liver metastases： A review of a 4-year experience at a single center ［J］. Int J Hyperthermia ， 2019 ， 36 （ 1 ）： 36 - 43 .

ARRU M ， ALDRIGHETTI L ， CASTOLDI R ， et al . Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer ［J］. World J Surg ， 2008 ， 32 （ 1 ）： 93 - 103 .

VIBERT E ， CANEDO L ， ADAM R . Strategies to treat primary unresectable colorectal liver metastases ［J］. Semin Oncol ， 2005 ， 32 （6 Suppl 8 ）： 33 - 39 .

刘学章 . 原发性肝癌TACE术后综合征临床表现及治疗［J］. 临床医学， 2004 ， 24 （ 1 ）： 22 - 23 .

CHAN D L ， ALZAHRANI N A ， MORRIS D L ， et al . Systematic review and Meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases ［J］. Surg Oncol ， 2015 ， 24 （ 3 ）： 162 - 171 .

D'ANGELICA M I ， CORREA-GALLEGO C ， PATY P B ， et al . Phase Ⅱ trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer： Conversion to resection and long-term outcomes ［J］. Ann Surg ， 2015 ， 261 （ 2 ）： 353 - 360 .

MCAULIFFE J C ， QADAN M ， D'ANGELICA M I . Hepatic resection， hepatic arterial infusion pump therapy， and genetic biomarkers in the management of hepatic metastases from colorectal cancer ［J］. J Gastrointest Oncol ， 2015 ， 6 （ 6 ）： 699 - 708 .

邓伟民，杨星 . 加味茵陈蒿汤治疗原发性肝癌栓塞化疗后发热48例［J］. 江苏中医， 1998 ， 19 （ 2 ）： 30 - 31 .

徐伯平，黄国贤，胡丕丽，等 . 清热柔肝法防治肝癌栓塞化疗后综合征的研究［J］. 癌症， 2000 ，（ 8 ）： 804 - 806 .

ALIBERTI C ， FIORENTINI G ， MUZZIO P C ， et al . Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead， drug-eluting bead loaded with irinotecan： Results of a phase Ⅱ clinical study ［J］. Anticancer Res ， 2011 ， 31 （ 12 ）： 4581 - 4587 .

LEE S H ， HAHN S T ， PARK S H . Intraarterial lidocaine administration for relief of pain resulting from transarterial chemoembolization of hepatocellular carcinoma： Its effectiveness and optimal timing of administration ［J］. Cardiovasc Intervent Radiol ， 2001 ， 24 （ 6 ）： 368 - 371 .

ROMANO M ， GIOJELLI A ， TAMBURRINI O ， et al . Chemoembolization for hepatocellular carcinoma： effect of intraarterial lidocaine in peri- and post-procedural pain and hospitalization ［J］. Radiol Med ， 2003 ， 105 （ 4 ）： 350 - 355 .

AGRAWAL R ， MAJEED M ， AQEEL S B ， et al . Identifying predictors and evaluating the role of steroids in the prevention of post-embolization syndrome after transarterial chemoembolization and bland embolization ［J］. Ann Gastroenterol ， 2021 ， 34 （ 2 ）： 241 - 246 .

中华人民共和国国家卫生健康委员会医政医管局 . 原发性肝癌诊疗规范（2019年版）［J］. 临床肝胆病杂志， 2020 ， 36 （ 2 ）： 277 - 292 .

中国医师协会外科医师分会，中华医学会外科分会胃肠外科学组，中华医学会外科分会结直肠外科学组，等 . 中国结直肠癌肝转移诊断和综合治疗指南（V2020）［J］. 中华胃肠外科杂志， 2021 ， 24 （ 1 ）： 1 - 13 .

国家市场监督管理总局，国家标准化管理委员会 . 中医临床诊疗术语［M］. 北京：中国标准出版社， 2021 .

杨威，芮兵，唐世早 . 奥沙利铂联合表柔比星经肝动脉化疗栓塞术治疗原发性肝癌的临床观察［J］. 实用癌症杂志， 2017 ， 32 （ 12 ）： 1996 - 1998 .

KAN X F ， WANG Y ， LIN G C ， et al . Radiofrequency ablation combined with transarterial chemoembolization for liver metastases from gastrointestinal cancers ［J］. J Huazhong Univ Sci Technolog Med Sci ， 2016 ， 36 （ 2 ）： 200 - 204 .

李小寒，尚少梅 . 基础护理学［M］. 6版 . 北京：人民卫生出版社， 2017 ： 282 - 288 .

National Institutes of Health ， National cancer institute . common terminology criteria for adverse events （CTCAE） version 5.0 ［DB/OL］. 2017 . https： //ctep.cancer.gov/ protocoldevelopment/ electronic _ applications /docs/CTCAE_v5_Quick_Reference_5x7.pdf https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf .

王冠军，郝捷 . 肿瘤学概论［M］. 北京：人民卫生出版社， 2013 ： 125 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of Shenqi Yiliu Prescription Combined with Cisplatin on H22 Liver Cancer-bearing Mice Based on NLRP3/Caspase-1/GSDMD Pyroptosis Pathway

Efficacy Evaluation of Biejiajianwan in the Treatment of Primary Liver Cancer Based on Real-world Data of Traditional Chinese Medicine

Data Mining-Based Macroscopic Exploration of Clinical Medication of Chinese Medicine for Liver Cancer

Effect of Yingyang Gongji Wan Contained Serum on Inhibiting HepG2 Cell Proliferation and Invasion, and Inducing Apoptosis

Effect of Cinobufagin Injection on Prevention of Recurrence of Primary Liver Cancer with Radical Resection

Related Author

YANG Yuping

HE Lanlan

FENG Xin

ZHANG Mingyu

MA Lan

LI Yarong

ZHU Zhongbo

YANG Mengying

Related Institution

Basic Medical College，Gansu University of Chinese Medicine

Key Laboratory of Ministry of Education of Traditional Chinese Medicine Prevention and Treatment of High-Incidence Diseases in Ningxia

Key Laboratory of Study on Integrated Traditional Chinese and Western Medicine with High Incidence Diseases in Ningxia

Gansu Province Experimental Animal Industry Technology Center

General Hospital of Ningxia Medical University

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰